4//SEC Filing
KAKKIS EMIL D 4
Accession 0000950170-25-032779
CIK 0001515673other
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 8:10 PM ET
Size
13.0 KB
Accession
0000950170-25-032779
Insider Transaction Report
Form 4
KAKKIS EMIL D
DirectorPresident & CEO10% Owner
Transactions
- Award
Common Stock
2025-03-01+43,268→ 607,873 total - Award
Common Stock
2025-03-01+107,292→ 715,165 total - Sale
Common Stock
2025-03-03$42.10/sh−73,434$3,091,571→ 641,731 total - Sale
Common Stock
2025-02-28$42.48/sh−25,000$1,062,000→ 2,158,985 total(indirect: By Trust) - Award
Stock Option (Right to Buy)
2025-03-01+78,448→ 78,448 totalExercise: $42.92Exp: 2035-03-01→ Common Stock (78,448 underlying)
Footnotes (7)
- [F1]Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
- [F2]Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric.
- [F3]Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.89 to $42.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F6]On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
- [F7]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Documents
Issuer
Ultragenyx Pharmaceutical Inc.
CIK 0001515673
Entity typeother
Related Parties
1- filerCIK 0001248093
Filing Metadata
- Form type
- 4
- Filed
- Mar 3, 7:00 PM ET
- Accepted
- Mar 4, 8:10 PM ET
- Size
- 13.0 KB